Torrent Pharmaceuticals reports that its consolidated net profit falls about 9–10% to ₹534 crore in the September quarter, even as revenue from operations jumps by roughly 51% to ₹4,979 crore.
Across outlets, the reported year-on-year comparison is consistent: net profit is down from ₹591 crore a year earlier, while revenue rises from ₹3,302 crore. One source also includes additional segment detail, saying India revenue increases to ₹2,181 crore and US revenue to ₹417 crore, with Brazil up and Germany down on a year-on-year basis. It also notes total expenses increase sharply, reaching ₹4,222 crore versus ₹2,471 crore a year earlier.
The difference in coverage is mainly presentation and emphasis. Times of India and Business Line both focus on the headline contrast between falling profit and rising revenue, with Business Line additionally specifying the company’s revenue from operations figure and the prior-year comparison.
